 musk-mg trial
reiter buy rate
catalyst report earn result corpor updat compani
launch firdaps treatment lem januari breadth prescrib
number patient enrollment/start form point strong earli launch
momentum manag also note minim pushback payer
cover patient pay less per month pocket believ
earli launch metric significantli eas investor concern drug
uptak recent washington polit grandstand also believ data
catalyst musk-mg provid addit upsid
catalyst financi upcom mileston
tr target
encourag earli launch momentum minim pushback payer
approv firdaps amifampridin neuron potassium channel
blocker treatment lambert-eaton myasthen syndrom lem
novemb catalyst initi launch januari breadth
prescrib number patient enrollment/start form catalyst
pathway point strong launch momentum addit compani
seen posit respons payer includ express script
macdonald buy aetna david macdonald buy prime
therapeut privat repres cross shield
privat plan across
march catalyst lem patient enrol catalyst pathway patient
current treat firdaps physician prescrib drug manag also
note high level formula replac reimburs commerci govern
medicar channel specif patient receiv posit coverag
reimburs decis averag monthli out-of-pocket amount patient
pay per month moreov time fill time reimburs metric current
trend better origin assumpt day compani plan provid revenu
guidanc earn call
rais awar identifi undiagnos misdiagnos lem patient
patient previous investig via jacobu pharmaceut catalyst
expand access compani expect finish transit
lem diagnos patient naiv far patient previous
unabl obtain investig compound alreadi enrol via catalyst
compani plan rais awar diseas via patient physician educ program
identifi undiagnos misdiagnos lem patient patient instanc compani
host catalyst lem firdaps ambassador fellow program educ patient commun
young neurologist ensur proper diagnosi lem sale forc region account manag
also engag activ commun neurologist neuromuscular specialist addit
non-person promot tool stimul growth firdaps launch
view berni sander request allow distribut fda-unapprov
uninform lack merit
februari reuter news note senat sander urg regul allow pharmaci
manufactur resum distribut fda unapprov version firdaps
patient treatment lem news sourc cite preced makena k-v
privat nr support potenti sander request believ makena
k-v reason comparison catalyst firdaps
unlik k-v makena never approv fda compound legal
speak pharmaci allow compound firdaps
firdaps rel short therapeut window make compound challeng
thu believ fda unlik allow pharmaci manufactur resum distribut
unapprov version firdaps
label expans firdaps provid addit signific valu top-lin data
phase trial
catalyst current conduct three clinic trial firdaps neuromuscular indic
phase trial firdaps congenit myasthen syndrom on-going expect
target enrol complet top-lin data believ snda file
success phase trial lead sizabl appreci share price like
approv second indic estim total firdaps revenu
out-year model
phase studi firdaps treatment musk antibodi posit myasthenia gravi musk-
mg continu special protocol assess spa compani expect complet
enrol patient report top-lin data view result
previou phase iib proof-of-concept trial demonstr clinic improv statist
signific fda requir primari endpoint mg-adl signific read-through
on-going phase studi project total firdaps revenu musk-mg
phase ii data proof-of-concept trial sma type expect enrol
patient europ posit data studi provid addit upsid estim
includ sma program model
page
addit compani develop long-act firdaps treatment lem
lower frequenc dose perhap twice daili dose frequenc current high
three four time daili
catalyst report ep slightli better estim
consensu decemb compani cash invest
debt manag believ suffici fund oper next month without
consid potenti revenu firdaps lem anticip equiti rais
potenti posit data cms/musk-mg trial support potenti launch firdaps
new indic reaffirm buy rate pt
page
research develop
gener administr
incom oper
interest incom
chang fair valu warrant liabil
provis incom tax
close price
requir disclosur last tab workbook
gaap ep basic dilut
weight averag share outstand basic dilut
suntrust robinson humphey estim compani report
page
close price
requir disclosur last tab workbook
